This article was originally published in The Gray Sheet
UK MHRA alert cites five instances of the implantable drug pump malfunctioning following use with diamorphine. While the firm stresses that such use is off-label, the healthcare agency notes the drug was omitted from an updated list of incompatible medications provided by the company last October. Medtronic plans to update the UK list to include diamorphine, which is banned in the U.S. MHRA released a similar alert following the initial pump "Educational Brief," citing inclusion of pump-compatible medications not approved for intrathecal use, as well as other additives that could damage the device (1"The Gray Sheet" Nov. 11, 2002, p. 12) ...
You may also be interested in...
Medtronic's SynchroMed implantable drug pump poses medication error risk due to an inaccurate listing of intrathecal drugs, an Oct. 31 device alert by the UK's Medical Devices Agency indicates
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.
ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.